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Refractory oesophagitis (non-healing of erosions) is rare since 
the advent of potent gastric acid inhibition with proton pump 
inhibitors (PPIs). However, refractory gastro-oesophageal reflux 
disease (GORD) symptoms, both typical and atypical (cough, 
chronic hoarseness, asthma and atypical chest pain), have become 
a substantial clinical problem that is most prevalent in patients 
with non-erosive reflux disease.
What defines GORD as refractory to treatment is controversial. 
Some clinicians believe that only patients with an incomplete 
response or lack of response to PPIs twice daily should be 
considered as PPI failures, while others regard a lack of symptomatic 
response to once-daily PPI as sufficient evidence. The frequency 
and/or severity of GORD-related symptoms are likely to vary 
between patients, making it difficult to decide which symptomatic 
burden fulfills the definition of refractory GORD. Therefore, a too 
restrictive definition of refractory GORD may exclude many true 
sufferers.1
Approximately 10 - 40% of GORD patients do not have a complete 
or even partial symptomatic response to a standard PPI dosage, 
hence the increasing practice of doubling the dose.2  Furthermore, 
less than 50% of the GORD patients are satisfied with their 
medical treatment, and only 58% of those receiving a PPI report a 
satisfactory therapeutic response.3
Endoscopic healing and symptom relief are achieved within 
8 weeks in the majority of patients with GORD.4  However, 
patients with severe oesophagitis (e.g. Los Angeles grade C and D 
oesophagitis) may take longer to heal.  Many of the possible causes 
for non-response are easy to address, but the timing and sequence 
of diagnostic testing, especially impedance pH studies, are more 
difficult and problematic.
Refractory GORD:  possible causes of  
s ymptoms
Patients unresponsive to PPIs comprise a group who may require 
more aggressive therapy and another who need an underlying cause 
defined. Causes of persistent symptoms despite twice-daily PPI 
therapy include poor compliance and improper dosing of PPIs.
Inadequate PPI response
The efficacy of the PPIs is dose dependent and the healing of 
oesophagitis is proportional to the fraction of the day that the pH 
is above 4.5  Nocturnal acid breakthrough, defined as intragastric 
pH<4 for more than an hour in the overnight period, is observed 
in up to 70% of normal subjects on PPIs taken twice daily and 
may be responsible for the majority of patients with refractory 
GORD.6 Other factors that may also contribute include decreased 
bioavailability, variations in drug metabolism, acid hypersecretion 
and Helicobacter pylori status.  The bioavailability of the different 
PPIs varies but does not normally lead to clinically relevant 
significant differences in acid suppression.7 Although timing of PPI 
ingestion with respect to meals has little influence on absorption, 
it is generally recommended that these drugs should be taken 15 
- 30 minutes before meals to reach peak serum levels prior to meal-
stimulated acid secretion.8  Genetically determined differences in 
PPI metabolism and, more specifically, rapid metabolism associated 
with mutation in the 2C19 isoform of cytochrome p450, may 
influence their efficacy.  However, drug resistance is a rare condition 
and is presumably caused by mutations of the proton pump. The 
role, if any, of Helicobacter pylori in patients with refractory GORD 
on adequate PPI treatment still needs to be defined. 
Other causes of symptoms
If a patient stays symptomatic despite adequate acid suppression, 
factors implicated in this include weakly acid reflux, duodenogastric/
bile reflux, oesophageal hypersensitivity, concomitant functional 
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bowel disease, psychological co-morbidities, 
delayed gastric emptying and eosinophilic 
oesophagitis.9 
Weakly acidic GORD is the reflux of gastric 
contents with a pH between 4 and 7 into 
the oesophagus and may be associated 
with typical reflux symptoms as well as 
regurgitation and a sour or bitter taste in the 
mouth.  In one study of patients who failed 
PPI therapy twice daily 31% had positive 
symptom index (SI) with weakly acidic 
reflux, 11% had acidic reflux, and 58% had a 
negative SI.  Interestingly, atypical symptoms 
were least likely to be preceded by a weakly 
acidic reflux event.10
Duodenogastro-oesophageal reflux (DGOR) 
is the reflux of duodenal contents through the 
stomach and into the oesophagus.  It has been 
shown in a recent study to be significantly 
more common (64%) than acid reflux (37%) 
in patients who continued to have GORD-
related symptoms on either standard-dose 
or double-dose PPI treatment. Patients with 
erosive oesophagitis who did not respond to 
PPI treatment experienced a higher number 
of DGOR episodes (35 v. 15.5) and longer 
exposure time to DGOR (11.9% v. 6.3%) 
than non-erosive reflux patients in whom 
PPI therapy failed.11
The role of visceral hypersensitivity has not 
been specifically studied in patients who 
failed PPI treatment. However, most patients 
who do not respond to PPI therapy have 
non-oesophageal reflux disease (NORD) 
and up to 50% have functional heartburn. 
It is hypothesised that functional heartburn 
is composed of a heterogeneous group of 
patients of whom a significant subset is 
unlikely to have GORD as the underlying 
stimulus for their heartburn.12 Furthermore, 
studies evaluating patients who did not 
respond to PPI treatment twice daily 
demonstrated that approximately 50 - 60% 
have negative SI between symptoms and any 
type of gastro-oesophageal reflux.
Delayed gastric emptying has been shown 
to contribute to the failure of PPI therapy 
in patients with GORD. Thus far, there are 
very few studies that have evaluated the 
frequency of gastric emptying in patients 
who did not respond to PPI therapy. 
Nevertheless, the rapidly growing number 
of patients with diabetes mellitus and those 
using narcotics for pain syndrome might 
soon make gastroparesis one of the leading 
causes of PPI failure.
Eosinophilic oesophagitis is relatively 
uncommon and unlikely to be responsible 
for a significant portion of patients who fail 
PPI treatment. The relationship between 
GORD and eosinophilic oesophagitis has 
not yet been fully explored. GORD-related 
symptoms only affect up to 43% of adults 
with eosinophilic oesophagitis, who in 
many instances present with dysphagia or 
have a history of food impaction. These are 
alarm symptoms necessitating urgent upper 
gastrointestinal endoscopy. 
Lastly, in a recent review of the literature 
on GORD and psychological co-morbidity it 
was concluded that this is common among 
GORD patients and appears to afflict all 
GORD phenotypes. Sexual and physical 
abuse is also common in GORD patients. 
Stress enhances perception of oesophageal 
acid exposure. Treatment for GORD, 
especially in those who are not responsive 
to antireflux treatment, may require further 
evaluation for psychological co-morbidity. 
The role of psychological co-morbidity and 
emotional stress in PPI failure has been 
scarcely studied.13 
Additional studies
Most of the available diagnostic approaches 
used in this challenging patient population 
group have limited clinical application 
and lack supportive evidence. Additional 
testing mostly requires referral to specialied 
centres.
Repeat upper endoscopy
Patients who had a limited initial examination 
or severe erosive oesophagitis, may benefit 
from a repeat endoscopy. However, the 
presence of oesophageal erosions may be 
indicative of poor compliance. Biopsies of 
persistent ulcerative lesions are imperative 
to exclude oesophageal carcinoma. It may 
also be helpful to exclude other causes 
of oesophagitis such as infection or pill 
oesophagitis by repeat endoscopy. 
Oesophageal pH monitoring
In patients with persistent typical GORD 
symptoms despite twice daily PPI therapy, 
standard transnasal oesophageal pH 
monitoring is most likely to be normal, 
but where adequate acid suppression is 
in question, a 24-hour pH study while 
taking medications can help to quantify 
the effectiveness of acid control.14 The 
use of a wireless pH capsule to extend the 
period of pH recording to 48 hours failed to 
demonstrate additional diagnostic benefit 
and was technically associated with a high 
failure rate.15 
Oesophageal impedance and pH 
monitoring (MII)
MII with pH sensor allows the detection 
of acidic (pH<4), weakly acidic (4≥pH<7), 
and weakly alkaline (pH≥7) reflux and can 
also determine the characteristics of the 
gastric refluxate (gas, liquid, mixed gas and 
liquid). Combined 24-hour pH impedance 
pH monitoring has demonstrated that 
persistent symptoms in patients on twice-
daily PPIs may be related to non-acid reflux 
in a subset of patients as determined by 
either the symptom index or the symptom 
association probability.16 The importance of 
proximal spread of the reflux column along 
with sensitisation of the oesophagus by 
prior reflux events as a cause of heartburn 
symptoms was highlighted in a recent 
publication.17  
Oesophageal manometry
This is indicated in patients in whom a 
motility disorder is suspected. In addition, 
in patients with symptoms compatible with 
dyspepsia, irritable bowel syndrome or 
delayed gastric emptying, the appropriate 
diagnostic tests should be done.
Therapeutic approach
All patients suspected of experiencing PPI 
failure should be assessed for compliance. 
GORD is primarily a symptom-driven 
disease in which many patients continue to 
take medications as long as they experience 
symptoms. 
Optimising therapy
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•    Increasing the frequency of dosing and 
additionally taking a PPI before dinner 
to reduce nocturnal acid breakthrough. 
Patients should be reminded to take 
their medications 15 - 30 minutes before 
meals.  
•    A stepwise increase in the total PPI dose to 
achieve adequate acid suppression – even 
in patients who initially failed standard or 
relatively high-dose therapy.  
•    The addition of an H2-receptor antagonist 
at night to suppress nocturnal acid 
breakthrough.  It may be of theoretical 
benefit, but the effect may be short-lived 
as tolerance develops quickly, especially in 
patients who regularly take a night-time 
H2 -receptor antagonist.18 Furthermore, 
the long-term efficacy of this approach is 
questionable as H2-receptor antagonists 
are less effective than PPIs when used as 
maintenance treatment.
•    Substituting one PPI for another. 
Very limited data are available on the 
effectiveness of this approach.  However, 
in one controlled trial, switching patients 
with persistent heartburn on a standard-
dose PPI to a different PPI was as effective 
as increasing the PPI dosage to twice daily 
for controlling heartburn symptoms.19
Lifestyle modifications 
Lifestyle modifications (weight loss, smoking 
cessation, avoidance of large meals, etc.), 
may benefit individual patients, but this is 
yet to be proven.  
Other therapeutic options
Baclofen, a gamma-aminobutyric acid 
ß-receptor agonist with inhibitory effect 
on transient lower oesophageal sphincter 
relaxation, has been shown to significantly 
reduce weakly acidic reflux and DGOR 
exposure as well as DGOR-related 
symptoms as compared with baseline. 
However, baclofen might result in a variety 
of side-effects such as confusion, dizziness, 
lightheadedness, drowsiness, weakness, and 
trembling.
The role of promotility drugs, pain 
modulators, bile acid binders and sucralfate 
is yet to be elucidated.
Surgery 
Antireflux surgery should be considered 
in patients who require high doses of PPIs 
to control symptoms, particularly young 
patients who may require lifelong therapy.20 
Antireflux surgery has also been suggested 
to be effective in selected patients who failed 
PPI twice daily and have clear evidence of 
increased weakly acidic reflux when using 
MII. However, patients with continued 
symptoms despite adequate acid inhibition 
may not benefit from a surgical approach 
and this should rather serve as a warning 
that these symptoms may have a different 
aetiology. 
Conclusion
Refractory GORD is a complex clinical 
problem with especially GORD-related 
(both typical and atypical) symptoms that 
are becoming increasingly more resistant to 
PPIs.  Optimising therapy is required before 
extensive testing with a rather limited yield 
is undertaken to define a possible underlying 
cause.
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In a nutshell 
•    Refractory oesophagitis (non-healing of erosions) is rare since the advent of potent gastric acid inhibition with proton pump inhibitors 
(PPIs).
•    The frequency and/or severity of GORD-related symptoms are likely to vary between patients, making it difficult to decide which 
symptomatic burden fulfills the definition of refractory GORD.
•    Endoscopic healing and symptom relief is achieved within 8 weeks in the majority of patients with GORD.
•    Patients unresponsive to PPIs comprise a group who may require more aggressive therapy and another who need an underlying cause 
defined.
•    Causes of persistent symptoms despite twice-daily PPI therapy include poor compliance and improper dosing of PPIs.
•    The efficacy of the PPIs is dose dependent and the healing of oesophagitis is proportional to the fraction of the day that the pH 
is above 4.
•    If a patient stays symptomatic despite adequate acid suppression, factors implicated in this include weakly acid reflux, duodenogastric/
bile reflux, oesophageal hypersensitivity, concomitant functional bowel disease, psychological co-morbidities, delayed gastric emptying 
and eosinophilic oesophagitis.
•    All patients suspected of experiencing PPI failure should be assessed for compliance.
•    Lifestyle modifications (weight loss, smoking cessation, avoidance of large meals, etc.), may benefit individual patients, but this is yet 
to be proven.  
•    Antireflux surgery should be considered in patients who require high doses of PPIs to control symptoms, particularly young patients 
who may require lifelong therapy.
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Single Suture
More girls than boys born in the tropics
Women living in tropical latitudes have a greater chance of giving birth to a girl, according to the first global study to link geographical 
latitude with the sex ratio of births. Normally, slightly more boys than girls are born.
Kristen Navara of the University of Georgia in Athens analysed birth data between 1997 and 2006 from 202 countries collected by the 
US Central Intelligence Agency. Navara’s analysis of CIA data suggests that, worldwide, boys account for 51.3% of births, with just over 
105 boys born for every 100 girls. But in tropical countries only 51.1% of births are boys. In the Central African Republic (CAR), only 
49% of births were boys.
The differences are very small, but they translate into thousands of babies every year. In the CAR, for example, 1 400 fewer boys 
were born in 2006 than if the sex ratio had been 50:50. Other ‘girl rich’ tropical countries included Grenada, Mauritius and Bermuda. 
Apparently the results are similar to those from other studies of mammals, including meadow voles and Siberian hamsters, which have 
fewest males when the days are shortest. Navara thinks that the variation in the circadian hormone melatonin is a factor.
New Scientist 4 April 2009: 11.
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